文献速递主动脉疾病

全球血管内主动脉治疗注册研究:胸主动脉腔内修复术治疗B型主动脉夹层的5年结局

Five-year outcomes of endovascular treatment for aortic dissection from the Global Registry for Endovascular Aortic Treatment.
PubMed 文献 · J Vasc Surg · 2024-05-31

该研究基于GREAT国际前瞻性多中心注册研究,分析265例接受胸主动脉腔内修复术的B型主动脉夹层患者5年随访数据,结果显示全因死亡免除率71.1%、主动脉相关死亡免除率95.8%,无支架移位、压缩或断裂,作者认为Gore TAG及Conformable Gore TAG胸腔内假体在B型主动脉夹层治疗中可得到支持。

要点

  • 5年全因死亡免除率为71.1%,主动脉相关死亡免除率为95.8%。
  • 5年内再干预率为21.1%(n=56),转为开放手术率为2.6%(n=7)。
  • 5年内无支架移位、压缩或断裂病例。

核心结论

  • 5年随访结果证明Gore TAG及Conformable Gore TAG胸腔内假体在急慢性、复杂或非复杂B型主动脉夹层治疗中可得到支持。
  • 数据表明器械耐久性强、患者结局有益,支持采用血管内方法治疗胸主动脉夹层。
  • 按计划完成GREAT注册研究的10年随访将是有益的。

研究设计与样本

  • GREAT为国际前瞻性多中心注册研究,收集Gore主动脉内假体性能的真实世界数据,2010年8月至2016年10月共纳入5014例患者。
  • 研究人群为因B型主动脉夹层接受胸主动脉腔内修复术并完成5年随访(第0至2006天)的患者,共识别265例。
  • 平均年龄60.9±11.9岁(范围19-84岁),男性211例(79.6%);使用的器械为Gore TAG和Conformable Gore TAG胸腔内假体。
  • 265例中,228例(86.0%)接受初次血管内治疗(其中144例为超适应证使用[54.3%]),22例(8.3%)在既往血管内手术后接受再干预,15例(5.7%)在既往开放手术后接受再干预。

主要发现

  • Kaplan-Meier估计的5年全因死亡免除率为71.1%,5年主动脉相关死亡免除率为95.8%。
  • 随访期间复杂与非复杂疾病的全体死亡免除率无显著差异。
  • 30天和5年时,主动脉破裂率分别为1.1%(n=3)和1.9%(n=5),卒中率分别为1.1%(n=3)和4.2%(n=11),脊髓缺血事件率分别为1.5%(n=4)和2.6%(n=7)。
  • 30天和5年时,再干预率分别为6.4%(n=17)和21.1%(n=56),转为开放手术率分别为0.4%(n=1)和2.6%(n=7),额外放置移植物分别为3例(1.1%)和16例(6.0%)。
  • 30天内漏率为3.4%(n=9),其中IA型1例(0.4%)、IB型4例(1.5%)、II型1例(0.4%)、III型1例(0.4%)、未明确4例(1.6%);5年内漏率为12.1%(n=32),其中IA型7例(2.6%)、IB型10例(3.8%)、II型9例(3.4%)、III型2例(0.8%)、未明确12例(4.5%);5年内无支架移位、压缩或断裂病例。

关键数值与推荐

  • 5年全因死亡免除率71.1%,5年主动脉相关死亡免除率95.8%。
  • 30天与5年主动脉破裂率分别为1.1%(n=3)与1.9%(n=5),卒中率分别为1.1%(n=3)与4.2%(n=11),脊髓缺血事件率分别为1.5%(n=4)与2.6%(n=7)。
  • 30天与5年再干预率分别为6.4%(n=17)与21.1%(n=56),转为开放手术率分别为0.4%(n=1)与2.6%(n=7)。
  • 30天与5年内漏率分别为3.4%(n=9)与12.1%(n=32)。

临床怎么用

  • 作者认为,Gore TAG及Conformable Gore TAG胸腔内假体在急慢性、复杂或非复杂B型主动脉夹层治疗中可得到支持。
  • 作者认为,数据支持采用血管内方法治疗胸主动脉夹层。
  • 作者认为,按计划完成GREAT注册研究的10年随访将是有益的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The Global Registry for Endovascular Aortic Treatment (GREAT) is an International prospective multicenter registry collecting real-world data on performance of Gore aortic endografts. The purpose was to analyze the long-term outcomes and patient survival rates, as well as device performance in patients undergoing thoracic endovascular aortic repair for acute and chronic and complicated or uncomplicated type B aortic dissection (TBAD). METHODS: From August 2010 to October 2016, 5014 patients were enrolled in the GREAT registry. The study population were patients treated with thoracic endovascular aortic repair for TBAD through 5-year follow-up (days 0-2006). The primary outcomes for this analysis were all-cause and aortic-related mortality, stroke, aortic rupture, endoleaks, migration, fracture, compression, and any reintervention through 5 years. RESULTS: We identified 265 patients. The mean age was 60.9 ± 11.9 years (range, 19-84 years; 211 males [79.6%]). Devices used were the Gore TAG and Conformable Gore TAG Thoracic Endoprosthesis. There were 228 patients (86.0%) who underwent primary endovascular treatment (144 off-label [54.3%]); 22 (8.3%) underwent reintervention after prior endovascular procedure and 15 (5.7%) underwent reintervention after prior open procedure. Kaplan-Meier estimated freedom from all-cause mortality at 5 years was 71.1%. Freedom from aortic-related mortality through 5 years was 95.8%. There was no significant difference in freedom from all-cause mortality during the follow-up period in complicated or uncomplicated disease. At 30 days and through 5 years, respectively, for all the following outcomes, the aortic rupture rate was 1.1% (n = 3) and 1.9% (n = 5). The stroke rate was 1.1% (n = 3) and 4.2% (n = 11). The spinal cord ischemic event rate was 1.5% (n = 4) and 2.6% (n = 7). Reinterventions were required in 6.4% (n = 17) and 21.1% (n = 56) of patients. The need for conversion to open repair was 0.4% (n = 1) and 2.6% (n = 7). Additional graft placement was required in 3 patients (1.1%) and 16 patients (6.0%). The endoleak rate at 30 days was 3.4% (n = 9); type IA (n = 1 [0.4%]), type IB (n = 4 [1.5%]), type II (n = 1 [0.4%]), type III (n = 1 [0.4%]), and unspecified (n = 4 [1.6%]). Through 5 years, the endoleak rate was 12.1% (n = 32); type IA (n = 7 [2.6%]), type IB (n = 10 [3.8%]), type II (n = 9 [3.4%]), type III (n = 2 [0.8%]), and unspecified (n = 12 [4.5%]). There were no cases of stent migration, compression or fracture through 5 years. CONCLUSIONS: Results at the 5-year follow-up demonstrate that the use of the Gore TAG and Conformable Gore TAG Thoracic Endoprosthesis can be supported in treatment of TBAD (acute, chronic, complicated, and uncomplicated). These data demonstrate strong device durability, beneficial patient outcomes, and support for the treatment of thoracic aortic dissection with an endovascular approach. Complete 10-year follow-up in GREAT as planned will be advantageous.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Payne D, Böckler D, Weaver F, et al. Five-year outcomes of endovascular treatment for aortic dissection from the Global Registry for Endovascular Aortic Treatment. J Vasc Surg. 2024. PMID: 38825212. doi:10.1016/j.jvs.2024.05.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。